In recent years, targeted protein degradation (TPD) has emerged as a promising approach to drug discovery, particularly for diseases with limited treatment options. By targeting previously “undruggable” proteins and harnessing the body’s natural protein degradation pathways, TPD has the potential to develop therapies that go beyond inhibition to actively eliminate disease-driving proteins.

BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, today announced the presentation of new findings in pancreatic cancer subtyping from Project Survival® (NCT2781012), the company’s 7-year-long longitudinal pancreatic cancer precision medicine clinical trial, at the ASCO Gastrointestinal Cancers Symposium, being held January 23–25, 2025, in San Francisco, Calif.

BPGbio, a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, is thrilled to announce its contribution to a groundbreaking study published in the January 10 issue of Science. This study describes the discovery of a novel lipid-rich tissue type, lipocartilage, which exhibits unique skeletal support properties distinct from classical cartilage rich in extracellular matrix proteins. This discovery has transformative implications for regenerative medicine and reconstructive surgery, offering new pathways for personalized cartilage tissue repair and replacement.